ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
Status:
Recruiting
Trial end date:
2033-02-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare in resectable colorectal cancer liver
metastasis patients.The main question it aims to answer is whether the 3-year
progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant
chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis
patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver
metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and
waiting" treatment strategy. The researchers will compare the outcomes between the two groups
to see if the PFS between the two groups is similar.